Apitolisib (GDC-0980, RG7422)

Apitolisib (GDC-0980, RG7422)は一種の有効なI型PI3K阻害剤で、無細胞試験でPI3Kα/β/δ/γに作用する時のIC50値が5 nM/27 nM/7 nM/14 nMそれぞれ分かれます。Apitolisib (GDC-0980, RG7422)も一種のmTOR阻害剤で、無細胞試験でKi値が17 nMになって、他のPIKK家族キナーゼに作用する選択性より高くなります。臨床2期。

価格 在庫  
USD 214 あり
USD 340 あり
USD 428 あり
USD 970 あり
電話番号: + 81 3-5632-9610mail@cosmobio.co.jp

Apitolisib (GDC-0980, RG7422) 化学構造
分子量: 498.6





  • Compare PI3K Inhibitors
  • 研究分野
  • Combination Therapy
  • Apitolisib (GDC-0980, RG7422)のメカニズム



製品説明 Apitolisib (GDC-0980, RG7422)は一種の有効なI型PI3K阻害剤で、無細胞試験でPI3Kα/β/δ/γに作用する時のIC50値が5 nM/27 nM/7 nM/14 nMそれぞれ分かれます。Apitolisib (GDC-0980, RG7422)も一種のmTOR阻害剤で、無細胞試験でKi値が17 nMになって、他のPIKK家族キナーゼに作用する選択性より高くなります。臨床2期。
ターゲット PI3Kα PI3Kβ PI3Kδ PI3Kγ mTOR
IC50 5 nM 27 nM 7 nM 14 nM 17 nM (Ki) [1]
In vitro試験 GDC-0980 shows the potent and selective inhibitory activities against class I PI3K and mTOR kinase versus a large panel of kinases with Ki of 17 nM for mTOR and IC50 of 5 nM, 27 nM, 7 nM, and 14 nM for PI3Kα, β, δ, and γ, respectively. [1] In vitro, GDC-0980 significantly inhibits cell proliferation in PC3 and MCF7 cells with IC50 of 307 nM and 255 nM, respectively. [1] A recent study shows that GDC-0980 reduces cancer cell viability by inhibiting cell-cycle procession and inducing apoptosis with most potency in prostate (IC50 < 200 nM 50%), <500 nM 100%), breast (IC50 <200 nM 37%, <500 nM 78%) and NSCLC lines (IC50 <200 nM 29%, <500 nM 88%) and less potency in pancreatic (IC50 <200 nM 13%, <500 nM 67%) and melanoma cell lines (IC50 <200 nM 0%, <500 nM 33%). [2]
In vivo試験 In both PC-3 and MCF-7 neo/HER2 xenograft models, GDC-0980 at a dose of 1 mg/kg, exhibits significant antitumor activity by causing tumor growth delay. Furthermore, GDC-0980 results in tumor stasis or regressions at the maximum tolerated dose of 7.5 mg/kg. [1] In mice, intravenous GDC-0980 administration at 1 mg/kg leads to low clearance (Clp: 9.2 mL/min/kg, Vss: 1.7 L/kg). While, oral administration at 5 mg/kg in 80% PEG400 and at 50 mg/kg as a crystalline suspension in 0.5% methylcellulose/0.2% Tween-80 also results in favorable pharmacokinetic parameters. [1]
臨床試験 GDC-0980 is currently in Phase II clinical trials in patients with recurrent or persistent endometrial carcinoma.
特集 A potent, selective, and orally available inhibitor of PI3Kα, β, δ, γ and mTOR.

プロトコル (参考用のみ)

キナーゼアッセイ: [1]

Enzymatic activity Enzymatic activity of the Class I PI3K isoforms is measured using a fluorescence polarization assay that monitors formation of the product 3,4,5-inositoltriphosphate molecule as it competes with fluorescently labeled PIP3 for binding to the GRP-1 pleckstrin homology domain protein. An increase in phosphatidyl inositide-3-phosphate product results in a decrease in fluorescence polarization signal as the labeled fluorophore is displaced from the GRP-1 protein binding site. Class I PI3K isoforms are expressed and purified as heterodimeric recombinant proteins. PI3K isoforms are assayed under initial rate conditions in the presence of 10 mM Tris (pH 7.5), 25 μM ATP, 9.75 μM PIP2, 5% glycerol, 4 mM MgCl2, 50 mM NaCl, 0.05% (v/v) Chaps, 1 mM dithiothreitol, 2% (v/v) DMSO at the following concentrations for each isoform: PI3Kα,β at 60 ng/mL; PI3Kγ at 8 ng/mL; PI3Kδ at 45 ng/mL. After assay for 30 minutes at 25°C, reactions are terminated with a final concentration of 9 mM EDTA, 4.5 nM TAMRA-PIP3, and 4.2 μg/mL GRP-1 detector protein before reading fluorescence polarization on an Envision plate reader. IC50s are calculated from the fit of the dose−response curves to a 4-parameter equation.Human recombinant mTOR(1360−2549) is expressed and purified from insect cells and assayed using a Lanthascreen fluorescence resonance energy transfer format in which phosphorylation of recombinant green fluorescent protein (GFP)-4-EBP1 is detected using a terbium-labeled antibody to phospho-threonine 37/46 of 4-EBP1. Reactions are initiated with ATP and conducted in the presence of 50 mM Hepes (pH 7.5), 0.25 nM mTOR, 400 nM GFP-4E-BP1, 8 μM ATP, 0.01% (v/v) Tween 20, 10 mM MnCl2, 1 mM EGTA, 1 mM dithiothreitol, and 1% (v/v) DMSO. Assays are conducted under initial rate conditions at room temperature for 30 minutes before terminating the reaction and detecting product in the presence of 2 nM Tb-anti-p4E-BP1 antibody and 10 mM EDTA. Dose−response curves are fit to an equation for competitive tight-binding inhibition and apparent Ki' s are calculated using the determined Km for ATP of 6.1 μM.

細胞アッセイ: [1]

細胞株 PC3 and MCF7.1
濃度 0 to 10 μM
反応時間 72 hours or 96 hours
実験の流れ Antiproliferative cellular assays are conducted using PC3 and MCF7.1 human tumor cell lines. MCF7.1 is an in vivo selected line and originally derived from the parental human MCF7 breast cancer cell line. Cell lines are cultured in RPMI supplemented with 10% fetal bovine serum, 100 units/mL penicillin, and 100 μg/mL streptomycin, 10 mM HEPES, and 2 mM glutamine at 3°C under 5% CO2. MCF7.1 cells or PC3 cells are seeded in 384-well plates in media at 1000 cells/well or 3000 cells/well, respectively, and incubated overnight prior to the addition of GDC-0980 to a final DMSO concentration of 0.5% v/v. MCF7.1 cells and PC3 cells are incubated for 3 days and 4 days, respectively, prior to the addition of CellTiter-Glo reagen and reading of luminescence using an Analyst plate reader. For antiproliferative assays, a cytostatic agent such as aphidicolin and a cytotoxic agent such as staurosporine are included as controls. Dose−response curves are fit to a 4-parameter equation and relative IC50s are calculated using Assay Explorer software.

動物実験: [1]

動物モデル PC3 and MCF7.1 cells are injected s.c. into the right hind flank of athymic nu/nu (nude) mice.
製剤 GDC-0980 is dissolved in 0.5% methylcellulose with 0.2% Tween-80 (MCT).
投薬量 ≤7.5 mg/kg
投与方法 Administered via p.o.

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDogMonkeyBaboon
Weight (kg)
Body Surface Area (m2)0.0070.0250.
Km factor361285201220
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)



Download Apitolisib (GDC-0980, RG7422) SDF
分子量 498.6


CAS No. 1032754-93-0
保管 3年-20℃
2年-80℃in solvent
別名 GNE 390
溶解度 (25°C) * In vitro DMSO 20 mg/mL (40.11 mM)
Water <1 mg/mL
Ethanol <1 mg/mL
In vivo 0.5% methylcellulose+0.2% Tween 80 30 mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
化学名 (S)-1-(4-((2-(2-aminopyrimidin-5-yl)-7-methyl-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)piperazin-1-yl)-2-hydroxypropan-1-one

文献中の引用 (6)



電話番号: +1-832-582-8158 Ext:3月曜日〜金曜日 9:00 AM–5:00 PM (米国中部標準時)


* 必須

Related PI3K 阻害剤

  • GDC-0032

    GDC-0032は一種有効的で、次世代のβ亜型PI3K阻害剤で、PI3Kα/δ/γに作用する時のIC50値が0.29 nM/0.12 nM/0.97nMそれぞれ分かれます。GDC-0032はPI3Kα/δ/γに作用する選択性はPI3Kβに作用する選択性より10倍以上が高くなります。

    Features:A beta isoform-sparing PI3K inhibitor.

  • Pilaralisib (XL147)

    Pilaralisib (XL147)は一種の選択性的で、可逆なI型PI3K阻害剤で、無細胞試験でPI3Kα/δ/γに作用する時のIC50値が39 nM/36 nM/23 nMそれぞれに分かれて、PI3Kβに低い作用をしています。臨床1/2期。

  • GNE-317


  • PI-3065

    PI-3065は一種の選択性p110δ阻害剤で、IC50値が15 nMです。PI-3065は選択性について、他のPI3K家族メンバーより70倍以上が高くなります。

  • LY294002

    LY294002は初めての周知されたPI3Kα/δ/βを抑制する小分子で、無細胞試験でIC50値が0.5 μM/0.57 μM/0.97 μM に分かれることですが、溶液にの状態はWortmanninにの状態よりもっと安定になりって、自食体の形成も遮断できます。

  • 3-Methyladenine (3-MA)

    3-Methyladenine (3-MA)は一種の選択性的なPI3K阻害剤で、HeLa細胞の中にVps34とPI3Kγに作用する時のIC50値が25μMと60μMに分かれることですが、I型PI3Kを永久性的に抑制しても、III型PI3Kを抑制することが一時になって、自食体の形成を遮断できます。

  • CAL-101 (Idelalisib, GS-1101)

    CAL-101 (Idelalisib, GS-1101)は1種のセレクティブp110δ阻害剤です。無細胞試験で、IC50値は2.5 nMです。CAL-101 (Idelalisib, GS-1101)はp110δに表現する選択性はp110α/β/γに表現する選択性 より40-300倍が高くなって、C2β、hVPS34、DNA-PK とmTORに表現する選択性より400-4000倍が高くなります。

  • Wortmannin

    Wortmanninは一種の初めての命名されたPI3K阻害剤で、無細胞試験でこのIC50値が3 nMですが、PI3K家族に作用する選択性は低くて、自食体の形成を抑制し、無細胞試験でDNA-PK/ATMを有効に抑制する時のIC50値が16 nMと150 nMに分かれます。

  • BEZ235 (NVP-BEZ235, Dactolisib)

    BEZ235 (NVP-BEZ235,Dactolisib)は一種の二重ATP競争性PI3KとmTOR阻害剤で、無細胞試験でp110α/γ/δ/β/mTOR(p70S6K)を抑制する時のIC50値は 4 nM /5 nM /7 nM /75 nM /6 nMそれぞれ分かれます。BEZ235 (NVP-BEZ235,Dactolisib)はT3TopBP1-ER 細胞の中でATRを抑制して、IC50 値が21 nMになって、Akt とPDK1に作用することが弱くなります。臨床2期。

  • BKM120 (NVP-BKM120, Buparlisib)

    BKM120 (NVP-BKM120, Buparlisib)は1種のセレクティブPI3K阻害剤で、無細胞試験でp110α/β/δ/γに作用する時のIC50値は52 nM/166 nM/116 nM/262 nMそれぞれに分かれます。BKM120 (NVP-BKM120, Buparlisib)はVPS34、mTORとDNAPKに作用する効果が良くなくて、PI4Kβにほとんど活性を表しません。臨床2期。


Tags: Apitolisib (GDC-0980, RG7422)を買う | Apitolisib (GDC-0980, RG7422)供給者 | Apitolisib (GDC-0980, RG7422)を購入する | Apitolisib (GDC-0980, RG7422)費用 | Apitolisib (GDC-0980, RG7422)生産者 | オーダーApitolisib (GDC-0980, RG7422) | Apitolisib (GDC-0980, RG7422)代理店
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID